Ketamine Pamoate Salt Formulation for Reduced CNS Side Effects

The patent changes the chemical parameter of ketamine by converting it from hydrochloride salt form to pamoate salt form. This parameter change resolves the technical contradiction by maintaining the therapeutic efficacy of ketamine while significantly reducing its harmful side effects including psychotic symptoms, dependence, and adverse effects on the nervous and urinary systems. The pamoate salt form achieves this through altered pharmacokinetic properties and reduced abuse potential compared to traditional ketamine hydrochloride.

The patent creates a composite pharmaceutical formulation by combining ketamine with pamoic acid to form a new salt compound. This composite material approach resolves the contradiction by integrating the therapeutic properties of ketamine with the safety profile of pamoate, resulting in a pharmaceutical composition that maintains efficacy while minimizing harmful effects such as psychosis, sedation, and urological complications.

The patent applies parameter change by transforming ketamine into its pamoate salt form, which alters the drug's pharmacokinetic and pharmacodynamic parameters. This change reduces the sedative effects and cognitive impairment associated with traditional ketamine administration while preserving the antidepressant and analgesic therapeutic effects, thereby resolving the contradiction between therapeutic benefit and harmful sedation.

The pamoate salt acts as an intermediary form of ketamine that mediates between the therapeutic effects and harmful side effects. By using pamoate as the salt form, the patent creates an intermediate state that maintains NMDA receptor antagonism for therapeutic benefit while reducing crosses into harmful pathways that cause sedation and cognitive impairment.

The patent changes the chemical parameter from ketamine hydrochloride to ketamine pamoate, which fundamentally alters the abuse liability parameter while preserving the rapid onset of action. The pamoate salt form maintains the quick antidepressant effect but reduces the euphoric and addictive properties, thereby resolving the contradiction between fast therapeutic onset and abuse potential.

The patent converts the potentially harmful property of rapid onset (which contributes to abuse liability) into a beneficial feature by using pamoate salt form. The rapid antidepressant effect is preserved and optimized, while the harmful abuse potential is transformed into reduced dependence risk, making the fast-acting property a blessing rather than a curse.